These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37572265)

  • 21. Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.
    Fuchs V; Kian W; Lichtenberg R; Cooper JM; Remilah AA; Levin D; Peled N; Roisman LC
    Clin Drug Investig; 2022 Feb; 42(2):185-192. PubMed ID: 35044639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
    Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A
    Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study.
    Almeida SB; Spencer AS; Santos CLD; Fernandes G; Simões P; Silva S; Domingues TD; Honório M
    Cancer Treat Res Commun; 2022; 31():100526. PubMed ID: 35114501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
    Shah MP; Neal JW
    Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
    Morimoto K; Yamada T; Sawada R; Azuma K; Goto Y; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Tanaka S; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
    Cancer Immunol Immunother; 2023 Jun; 72(6):1699-1707. PubMed ID: 36617602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.
    Patel J; Meng J; Le H; Tanaka Y; Phani S; Salas M; Wu C; Sternberg D; Esker S; Anderson JP; Crowley A; Zhou SQ; Lieb C; Sun H; Doan QV; Santhanagopal A; Reckamp KL
    Adv Ther; 2024 Aug; 41(8):3299-3315. PubMed ID: 38958845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.
    Patel S; Patel JD
    Adv Ther; 2023 Dec; 40(12):5579-5590. PubMed ID: 37801233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
    Li L; Huang Q; Sun J; Yan F; Wei W; Li Z; Liu L; Deng J
    Acta Oncol; 2022 Nov; 61(11):1347-1353. PubMed ID: 36240432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.